Company intelligence / Profile preview

New India Bio Pharma

New Delhi, Delhi, India

Ownership: Private
Development stage: Other

Overview

New India Biopharma is an Indian pharmaceutical and biotechnology company operating as the subsidiary of SGN Nanopharma. The company focuses on developing and commercializing clinically differentiated nanomedicines using its proprietary Micellar Nanoparticle (MNP) platform. Its pipeline includes SGN-101 (MNP Cyclosporine) for dry eye disease, SGN-624 for acute post-operative pain, and SGN-516 for diabetic neuropathy. By reformulating existing active pharmaceutical ingredients into highly bioavailable nano-formulations, New India Biopharma aims to deliver safer and more effective therapeutic options.

Therapeutic areas: ImmunologyNeurologyMen's HealthOphthalmologyEndocrinology
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Partnerships

EyenoviaMedicom HealthcareWellesta Healthcare

Beyond the preview

Go deeper on New India Bio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New India Bio Pharma.

Explore the full profile